GIT 27

GIT 27 is an orally active, isoxazole compound that exhibits various immunomodulatory properties both in vitro and in preclinical in vivo models of autoimmune diseases by inhibiting inflammatory antigen presentation.¹ It has been shown to target macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, macrophage migration inhibitory factor, and inducible nitric oxide synthase-mediated nitric oxide generation in both pancreatic islets and peripheral compartments.² GIT 27 can also prevent IL-1β/interferon-γ-induced pancreatic islet death in vitro at 10 µg/ml and reduce the cumulative incidence of diabetes and insulitis in a mouse model of type 1 diabetes at 20 mg/kg.²

WARNING This product is not for human or veterinary use.

1. Fagone, P., Muthumani, K., Mangano, K., et al. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. Immunology 142(4), 594-602 (2014).

2. Stosic-Grujicic, S., Cvetkovic, I., Mangano, K., et al. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J. Pharmacol. Exp. Ther. 320(3), 1038-1049 (2007).